Episode 13- Current Developments of Pharmacotherapeutic Spending

During this segment, David Calabrese, RPh, MHP, explores the current trends of pharmacotherapeutic spending for the treatment of chronic conditions.

Mr Calabrese explains that from a research and developmental stage, there has been a stronger trend toward investing within the specialty market, rather than on traditional products.

Over 30 new products have been approved in the United States over the past year, and this number is expected to continue to grow annually. For this reason, investors seem more interested in supporting today’s higher-cost, complex therapies rather than traditional products for the treatment of chronic conditions.